Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

CDER's Novel Approvals In 2018 Show Remarkable Review Consistency

Jan 25 2019

• By Bridget Silverman

Red Approved Stamp with Wooden handle Rubber Stamper Isolated on White Background.

Related Content

Orphan Drugs Compose Majority Of Novel US Approvals For First Time Ever In 2018

Jan 03 2019

US FDA’s Best Year Ever For New Drugs: CDER Novel Approvals Hit 59

Jan 01 2019

PDUFA V 'Program' First-Cycle Approval Rates Significantly Higher For All Applications

Dec 13 2016

Related Companies

AstraZeneca PLC

Eli Lilly and Company

Incyte Corporation

Advanced Accelerator Applications SA

Novartis AG

BioMarin Pharmaceutical Inc.

Leadiant Biosciences, Inc.

Johnson & Johnson

Stemline Therapeutics, Inc.

Pfizer Inc.

Sanofi

Regeneron Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc.

Roche Holding AG

Shionogi & Co. Ltd.

Alexion Pharmaceuticals Inc.

Gilead Sciences, Inc.

Teva Pharmaceutical Industries Ltd.

Celltrion, Inc.

Additional Topics

United States Drug Review Drug Approval Standards Review Pathway Regulation BioPharmaceutical Pink Sheet Perspectives

More from Product Reviews

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window